The CHOP's research team findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which ...

Recombinant adeno-associated virus (AAV) vectors are predominantly nonintegrating, but rare genomic integration events have been associated with oncogenesis in neonatal murine models. Here we ...

VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, will participate in the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place in ...

JCR announced today that it presented preclinical data from its novel platform technologies in oral and poster sessions at the ASGCT Annual Meeting.

Oral presentation at ASGCT showcases breakthrough technology enabling precise in vivo genome editing in the CNS using a ...

CHICAGO--(BUSINESS WIRE)--#BioTechNews--VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree™ AAV, a high-stability AAV vector designed to address ...

University of Zurich scientists demonstrated that they could reassemble and express large genes using a new dual adeno-associated viral (AAV) vector technology that depends on mRNA trans-splicing.

The FDA has approved Otarmeni, the first-ever gene therapy for genetic hearing loss caused by the OTOF gene, for both pediatric and adult patients after positive results.

Researchers have developed an engineered adeno-associated virus (AAV) vector that yields high transduction of brain vascular pericytes and smooth muscle cells. The study describing the ...

What Are AAV Vector-Based Therapies? Gene therapies are groundbreaking approaches utilizing viral and non-viral vectors. These vectors introduce therapeutic genes into patient cells to treat diseases, ...